Oculis

48 articles about Oculis

• Oculis Completes Enrollment in Phase 3 OCS-01 OPTIMIZE Trial

  3/16/2023

  Oculis Holding AG (Nasdaq: OCS) (“Oculis”) a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announces the completion of enrollment for its Phase 3 OPTIMIZE trial evaluating the efficacy and safety of once-daily OCS-01.

• Oculis Announces US Public Listing on NASDAQ

  3/3/2023

  Oculis Holding AG (“Oculis”) a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announces its listing on Nasdaq after successfully closing the business combination between European Biotech Acquisition Corp. (“EBAC”) and Oculis SA.

• Oculis completes patient recruitment for stage 1 of Phase 3 DIAMOND study evaluating the efficacy and safety of OCS-01 in diabetic macular edema (DME)

  1/5/2023

  Oculis S.A. announces the completion of enrollment for stage 1 of its Phase 3 DIAMOND study evaluating the efficacy and safety of OCS-01 in patients with diabetic macular edema.

• Oculis Strengthens its Scientific Advisory Board with World-Leading Ophthalmology Experts to Support Pipeline Development

  11/3/2022

  Oculis S.A. announced significant expansion of its Scientific Advisory Board with the appointments of six world-leading medical experts, Christophe Baudouin, M.D., PeterK.

• Oculis SA and European Biotech Acquisition Corp announce business combination agreement to create Nasdaq-listed biopharmaceutical company driving breakthrough innovations in ophthalmology

  10/17/2022

  Oculis, SA. (“Oculis”), a global biopharmaceutical company developing treatments to save sight and improve eye care with breakthrough innovations and European Biotech Acquisition Corp (“EBAC”, NASDAQ: EBAC), a special purpose acquisition company (SPAC), today announced they have entered into a definitive business combination agreement.

• Oculis announces publication and presentation of Phase 2 data showing topical OCS-01 improves macular thickness and visual acuity in patients with diabetic macular edema

  9/6/2022

  Oculis S.A. announces that the Phase 2 DX-211, a randomized, double blinded, multi-center and vehicle controlled clinical trial assessing the safety and efficacy of topical OCS-01 in patients with Diabetic Macular Edema has been published by the Acta Ophthalmologica journal.

• Oculis announces publication of Phase 2 data showing topical eye drops anti-TNFα agent licaminlimab (OCS-02) relieves persistent ocular discomfort in severe dry eye disease

  8/23/2022

  Oculis S.A. announces that the results of the double blinded, multicenter and placebo controlled Phase 2 clinical trial assessing the effect of topical licaminlimab on global ocular discomfort in patients with severe dry eye disease has been published by the Clinical Ophthalmology journal.

• Oculis Announces First Patient Enrolled in Phase 3 OPTIMIZE Trial of OCS-01 in the Treatment of Inflammation and Pain Following Cataract Surgery

  6/29/2022

  Oculis S.A. announced that the first patient has been enrolled in its Phase 3 OPTIMIZE trial evaluating the efficacy and safety of once-daily OCS-01, a novel, high concentration, preservative-free, topical OPTIREACH formulation of dexamethasone for the treatment of inflammation and pain following cataract surgery.

• 

  2023 Will Be Pivotal Year for Oculis’ Potentially Transformative Medicines

  4/4/2022

  Oculis has identified pressing unmet therapeutic needs and innovative, differentiated approaches to meet those needs.

• Oculis appoints Dr. Bastian Dehmel as Chief Development Officer

  2/8/2022

  Oculis S.A. announces the further strengthening of the Company’s executive leadership team with the appointment of Dr. Bastian Dehmel as global Chief Development Officer.

• Oculis appoints Mr. Webb Ding as Global Chief Operating Officer and General Manager (China)

  1/5/2022

  Oculis S.A. announces the appointment of Mr. Webb Ding as global Chief Operating Officer and General Manager, China, with effect from February 1, 2022.

• Oculis Announces Positive Data from Two Proof-of-Concept Phase 2 Trials with OCS-02, a Novel Topical TNF alpha Antagonist, in Dry Eye Disease and Acute Anterior Uveitis, Presented at ARVO 2021

  5/11/2021

  Positive Phase 2a data, presented for the first time, highlights the potential of OCS-02 to become a new treatment in moderate to severe DED and potentially the first personalized therapy in this disease.

• Oculis Announces an Oversubscribed US$57 million Series C Financing

  5/4/2021

  Advance novel, late-stage Investigationalophthalmology drugs OCS-01 and OCS-02 and deliver the first topical drug for retinal edema.

• Oculis appoints David Jacobs, M.D. as Chief Development Officer adding complementary drug development and regulatory expertise

  10/22/2020

  Oculis S.A., a biopharmaceutical company focused on developing transformative topical ophthalmic treatments to improve the sight and lives of patients, announces the appointment of David Jacobs, M.D., as Chief Development Officer.

• 

  BioSpace Global Roundup, Oct. 8

  10/8/2020

  Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.

• Oculis announces presentation of positive results from Phase 2 trial of OCS-01 in patients with Diabetic Macular Edema (DME) at EURETINA 2020 Virtual

  10/5/2020

  The study met its pre-specified efficacy endpoints and showed that OCS-01 eye drops were more effective than vehicle in reducing central macular thickness and improving visual acuity in patients with DME No significant unanticipated ocular adverse events were observed Phase 3 trial for OCS-01 in DME is in preparation following positive End-of-Phase 2 meeting with FDA Results were presented by renowned retina specialist Prof. Ramin Tadayoni, M.D., Ph.D. LAUSANNE, Switzerland, Oct. 05, 2020

• 

  BioSpace Global Roundup, Sept. 24

  9/24/2020

  Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses.

• Oculis Announces Successful End-of-Phase 2 Meeting with the FDA for OCS-01 in Two Ophthalmology Indications

  7/27/2020

  Oculis S.A., a biopharmaceutical company focused on developing transformative topical (eye drop) ophthalmic treatments using its innovative formulation technologies to improve the sight and lives of patients, today announced that it has successfully completed an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) for OCS-01 in two indicat

• Oculis Reports Positive Top-line Data From SKYGGN (Phase 2) Trial With OCS-01 for Treating Inflammation and Pain Following Cataract Surgery

  5/18/2020

  - OCS-01 meets primary endpoints demonstrating superior efficacy and safety vs vehicle in the treatment of inflammation and pain following cataract surgery with a once-daily regimen - SKYGGN is the second positive trial with OCS-01 highlighting its potential for treating both front-of-the-eye and retinal diseases such as DME - Positive results validate the Solubilizing NanoParticle (SNP) formulation technology in developing topical treatments for front-of-the-eye with less fr

• Oculis Announces Presentation of Results From Its Phase 2 (SKYGGN) Trial of OCS-01 for Inflammation and Pain Following Cataract Surgery at Upcoming ASCRS Annual Meeting 2020

  5/7/2020

  Oculis S.A. announces that a presentation of results from its Phase 2 clinical trial, evaluating the efficacy and safety of its drug candidate OCS-01 for the treatment of inflammation and pain following cataract surgery, will be made at the American Society of Cataract and Refractive Surgery Annual Meeting, which will be held online on May 16-17, 2020.